AiCuris

Update (23/02/2018): Merck Sharp & Dohme (MSD), licensee of AiCuris, has launched letermovir in Germany under the trade name Prevymis. The antiviral drug will be available to patients undergoing a hematopoietic…

AiCuris' candidate pritelivir has shown to perform better than current standard antiviral treatments against genital herpes in Phase II trials. AiCuris, leading the development of treatments for infectious disease, has…

Update (09/05/2017): AiCuris has started a Phase II trial, PRIOH-1, with the oral version of its herpes cure pritelivir.  Update (17/01/2017): The company has presented results from its first Phase…